Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.72 |
| ▸ | AR | P10275 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5740800 | 0.95 | KMT2A (0.66) | KMT2AARMEN1ALDH1A1TDP1 | |
| SCHEMBL13879545 | 0.84 | AR (0.60) | KMT2AARMEN1ALDH1A1POLB | |
| SCHEMBL5742240 | 0.84 | KMT2A (1.00) | KMT2AMEN1ALDH1A1TDP1GAA | |
| SCHEMBL12543889 | 0.84 | AR (0.56) | KMT2AARMEN1ALDH1A1TDP1 | |
| SCHEMBL11174171 | 0.84 | AR (0.64) | KMT2AARMEN1ALDH1A1GAA | |
| SCHEMBL5739481 | 0.84 | KMT2A (1.00) | KMT2AMEN1ALDH1A1TDP1GAA | |
| SCHEMBL13879579 | 0.83 | AR (0.60) | KMT2AARMEN1ALDH1A1POLB | |
| SCHEMBL10650530 | 0.83 | KMT2A (0.67) | KMT2AARMEN1ALDH1A1TDP1 | |
| SCHEMBL10798950 | 0.83 | KMT2A (0.67) | KMT2AARMEN1ALDH1A1TDP1 | |
| SCHEMBL10644699 | 0.83 | KMT2A (0.67) | KMT2AARMEN1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1244670-B1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | MGI GP INC (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6974823-B2 | Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same | GPI NIL HOLDINDGS, INC. (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1404325-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-10-30 | — | — | US | disclosed |
| WO-2002096420-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| US-20020058685-A1 | Hydantoin derivative compounds, pharmace utical compositions, and methods of using same | GLIAMED, INC. | 2002-05-16 | — | — | US | disclosed |
| WO-2001007052-A1 | SMALL MOLECULES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NGF, BDNF, GAP43 | KMT2A 4086/4885AR 447/4885MEN1 930/4885 |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | KMT2A 2463/4885AR 4274/4885MEN1 4395/4885 |
| US-20020058685-A1 | Hydantoin derivative compounds, pharmace utical compositions, and methods of using same | HNMT, HAAO, HTR3E | KMT2A 3409/4885AR 2055/4885MEN1 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.